VEGFA and small cell lung carcinoma: Prior clinical studies of anti-VEGF agents had demonstrated mixed efficacy in SCLC patients until the recent publication of ETER701, a Phase 3 trial for first-line treatment of ES-SCLC comparing benmelstobart, anlotinib, and platinum-etoposide or anlotinib and platinum-etoposide to platinum-etoposide (the standard of care in China at the time of trial design)[30,111-113].